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MYCN amplification and MYC signaling are associ-
ated with high-risk neuroblastoma with poor prog-
nosis. Treating these tumors remains challenging,
although therapeutic approaches stimulating differ-
entiation have generated considerable interest. We
have previously shown that the MYCN-regulated
miR-1792 cluster inhibits neuroblastoma differen-
tiation by repressing estrogen receptor alpha. Here,
we demonstrate that this microRNA (miRNA) cluster
selectively targets several members of the nuclear
hormone receptor (NHR) superfamily, andwe present
auniqueNHRsignatureassociatedwith thesurvival of
neuroblastoma patients. We found that suppressing
glucocorticoid receptor (GR) expression in MYCN-
driven patient and mouse tumors was associated
with an undifferentiated phenotype and decreased
survival. Importantly, MYCN inhibition and subse-
quent reactivation of GR signaling promotes neural
differentiation and reduces tumor burden. Our find-
ings reveal a key role for the miR-1792-regulated
NHRs in neuroblastoma biology, thereby providing a
potential differentiation approach for treating neuro-
blastoma patients.INTRODUCTION
Neuroblastoma is a childhood tumor that is believed to be
caused by aberrations during normal development of the neu-
ral-crest-derived sympathoadrenal lineage (Maris, 2010). ThisThis is an open access article under the CC BY-Ndisease exhibits heterogeneous clinical behavior, ranging from
low-risk tumors, with a remarkable ability to differentiate and
regress even with no or minimal therapy, to high-risk tumors
responsible for the highest number of cancer-related deaths in
infants (Brodeur, 2003). One of the few strong prognostic
markers of adverse outcome is amplification of the MYCN
gene, which has a prevalence of 40% in high-risk tumors and
an overall survival of less than 50% (Brodeur, 2003; Maris,
2010).MYCN is normally expressed in the developing peripheral
neural crest and sympathetic ganglia (Edsjo¨ et al., 2004; Waka-
matsu et al., 1997), and disruption of MYCN signaling leads to
decreased proliferation and terminal differentiation of neuronal
cells (Knoepfler et al., 2002). Interestingly, high-risk tumors
withoutMYCN amplification frequently display elevated expres-
sion levels of MYC signature genes (Fredlund et al., 2008; West-
ermann et al., 2008), suggesting a prominent role for MYC
signaling in aggressive neuroblastoma. It is well established
that the MYC proteins upregulate the oncogenic miR-1792 mi-
croRNA (miRNA) cluster (Love´n et al., 2010; O’Donnell et al.,
2005; Schulte et al., 2008). We have previously shown that
miR-18a and miR-19a from this cluster inhibit the differentiation
of neuroblastoma cells by repressing expression of estrogen re-
ceptor alpha (ER-alpha), a nuclear hormone receptor (NHR)
(Love´n et al., 2010). Furthermore, it has been proposed that
miRNAs are important in regulating and fine-tuning NHR action
at multiple levels (Pandey and Picard, 2010).
NHRs, comprising 48 human (Mangelsdorf et al., 1995) and 49
mouse (Bookout et al., 2006) genes, represent the largest tran-
scription factor superfamily in metazoans. These receptors
respond to a wide variety of ligands (Chawla et al., 2001). The
majority of NHRs bind DNA either as homo- or heterodimers,
and others recruit co-repressors or co-activators in the absence
and presence of ligand, respectively (Tata, 2002). NHRs play an
important role in controlling the fate of neural stem cells andCell Reports 16, 979–993, July 26, 2016 ª 2016 The Author(s). 979
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neural differentiation (Rada-Iglesias et al., 2012; Stergiopoulos
and Politis, 2013). Given that neuroblastoma arises from the
developing neural crest, we hypothesized that NHRs might
also play important roles in tumorigenesis and progression.
Here, we investigated the role of NHRs in neuroblastoma
biology in relation to MYC pathway activity. We found that the
expression of several NHR members correlated with increased
survival in neuroblastoma patients and with neural differentiation
in a MYCN-driven mouse model. Furthermore, we demonstrated
that the MYC-regulated miR-1792 cluster represses the genes
encoding the same NHRs, thereby inhibiting differentiation and
contributing to tumorigenesis. Importantly, pharmacological inhi-
bitionofMYCN, followedbyactivationof glucocorticoidsignaling,
led to a reduced tumor burden in a neuroblastomamousemodel.
Our results provide evidence for miR-1792-mediated deregula-
tion of NHRs in patients and emphasize a critical role for this
transcription factor family in neuroblastoma tumorigenesis.
RESULTS
The miR-1792 Cluster Targets the NHR Family
We have previously shown that miR-1792 members directly
target ER-alpha (ESR1) in neuroblastoma as a mechanism to
inhibit differentiation (Love´n et al., 2010), and we hypothesized
that additional members of the NHR family could be targeted
for repression. To identify cognate miR-1792 binding sites in
the 30 UTRs of all NHR family members, we used four indepen-
dent prediction algorithms and selected transcripts predicted
by at least three of these algorithms (Figures 1A and S1A; Tables
S1, S2, and S3). Of the 48 NHRs, 11 were predicted to contain
miR-1792 binding sites, representing a disproportional enrich-
ment of sites over the expected distribution (p = 0.01939; the
Fisher’s exact test (Tables S2–S4)). We extended our analysis
to the p160 nuclear receptor co-activator (NCOA) gene family,
whose members act as transcriptional co-activators for a broad
range of NHRs (Xu and Li, 2003; Xu et al., 2009), and found that
NCOA1 and NCOA3 were also consensus-predicted targets
(Figure 1A; Table S2).
Next, we sought to confirm our in silico predictions using a
neuroblastoma cell line with an inducible miR-1792 cluster
(Figures 1B and S1B;Mestdagh et al., 2010). Using a low-density
array to measure NHR expression levels, we determined that 28
of 48 NHR transcripts were detectable in these cells and that theFigure 1. Several NHRs Are Putative Targets of the miR-1792 Cluster
(A) Heatmaps depicting members of the nuclear hormone receptor (NHR) and nuc
Gene names are shown to the right and the miR-1792 members (miR-17, miR-1
of consensus algorithms that predict seed sequences for the different miRNAs i
highest consensus are presented in bold face.
(B) A schematic of the miR-1792 cluster (top) and their ‘‘seed region’’ sequence
from a doxycycline (dox)-inducible promoter in the SHEP neuroblastoma cell line
(C) A histogram showing differential mRNA expression of NHRs in SHEP-TR-miR-1
increased and decreased NHR gene expression levels, respectively. The circles
(D) Validation of identified NHR targets using qRT-PCR. Bars of consensus-predic
*p < 0.05; **p < 0.01; and ***p < 0.001, compared to the activity of the uninduced
(E) Luciferase assays of the indicated NHR 30 UTR-luciferase constructs co-trans
miR-18a (PM-18a), or pre-miR-19a (PM-19a). The dotted line indicates the lucifer
activity was also assessed using 30 UTR-NHR reporters with mutated seed sequ
mean ± SEM; *p < 0.05; **p < 0.01; and ***p < 0.001, compared to the luciferasemajority of the downregulated NHRs were predicted targets of
miR-1792 (8 of 11 consensus NHRs; Figure 1C; Table S3).
qPCR analysis confirmed that predicted and previously estab-
lished NHR targets, including ER-alpha, were downregulated
after activation of the miR-1792 cluster (Figures 1C and 1D).
We generated reporter plasmids by fusing the 30 UTRs of
several NHRs to the luciferase open reading frame and co-trans-
fected these constructs in HEK293T cells with control pre-miR,
pre-miR-17, pre-miR-18a, or pre-miR-19a, three members of
the cluster that were previously shown to be important in neuro-
blastoma tumorigenesis (Fontana et al., 2008; Love´n et al.,
2010). We found that miR-17 decreased the luciferase levels of
the NURR1 (also known as NR4A2), PPARD (NR1C2), and TR4
(NR2C2) constructs; whereas miR-18a decreased the luciferase
activity of the LXRb (NR1H2), PPARD (NR1C2), NURR1, and GR
(NR3C1) reporters; and that miR-19a led to decreased luciferase
levels of the PPARD and MR (NR3C2) constructs (Figure 1E).
Furthermore, the nuclear receptor co-activator NCOA1was vali-
dated as a target of miR-18a (Figure 1E). Mutating the respective
seed sequences rescued the decreased luciferase levels in all re-
porter plasmids (Figure 1E). In contrast, no significant changes in
luciferase activity were detected in the 30 UTR-luciferase re-
porters for THRA (NR1A1), THRB (NR1A2), RARB (NR1B2),
RORA (NR1F1), TR2 (NR2C1), or NOR1 (NR4A3) (Figure S1C).
Importantly, we identified GR, NURR1, MR, LXRb, PPARD,
TR4, and NCOA1 as direct targets of the miR-1792 cluster.
An NHR Signature Is Associated with Overall
Neuroblastoma Patient Survival
To evaluate the clinical relevance of NHRs in neuroblastoma, we
used a cohort of 649 untreated patients in all stages of disease
(Kocak et al., 2013) and searched for NHRs differently ex-
pressed inMYCN-amplified versus non-MYCN-amplified cases.
Six of the eleven consensus-predicted NHRs (NR3C1, NR3C2,
NR4A2, RORA, NR4A3, and ESR1) and the co-activator
NCOA1 were significantly downregulated in MYCN-amplified
patients (Figure 2A; Table S5). Importantly, at least five of these
seven genes are direct targets of miR-1792 (Figure 1E), with
GR (NR3C1) and NURR1 (NR4A2) ranking among the top
downregulated transcripts in MYCN-amplified neuroblastoma
(Figure 2A). By using these seven transcripts, we generated an
‘‘NHR score’’ (Table S6). Considering that both MYCN and
MYC can activate the miR-1792 cluster (Love´n et al., 2010;lear receptor co-activator (NCOA) families as targets of the miR-1792 cluster.
8, miR-19, miR-20, and miR-92) on top of the heatmaps. The key to the number
s shown below the heatmaps. The 11 NHR and the two NCOA genes with the
s (bottom). In SHEP-TR-miR-1792 cells, the miR-1792 cluster is expressed
.
792 cells, with high versus lowmiR-1792 expression. Red and blue indicate
represent algorithms predicting a particular gene as a target for the cluster.
ted targets are colored green. n = 5; the mean ± SEM is shown for quantitation;
miR-1792 cluster.
fected into HEK293T cells with pre-miR-scrambled, pre-miR-17 (PM-17), pre-
ase activity following transfection with pre-miR-scrambled plasmid. Luciferase
ences as indicated. Experiments were performed at least four times with the
activity of the pre-miR-scrambled plasmid.
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Figure 2. The NHR Score Is Associated with Survival in Neuroblastoma Patients
(A) Differentially expressed genes inMYCN-amplified versus non-MYCN-amplified neuroblastoma in a cohort of 649 untreated patients. Significantly differential
gene expression is marked by the dashed lines (q < 0.05 and log2-difference > 0.5). The positions of the predicted NHRs targets of miR-1792 are marked below
the graph.
(B) An ‘‘NHR score’’ was generated based on seven consensus-predicted NHRs or NHR-related targets (NCOA1, RORA, NR4A2, NR3C2, NR3C1, NR4A3,
and ESR1) and then sorted according to the expression levels represented in the histogram below the heatmaps. Gene expression data from 649 neuro-
blastoma patients were sorted and correlated to MYCN amplification, MYC signature, and expression levels of the individual NHRs represented in the NHR
score. Red indicates high expression whereas blue represents low expression levels. MYCN status is presented as amplified, normal gene copy number, or
unknown.
(C) Neuroblastoma patients (n = 649) categorized into four equal-size quartile groups based on their NHR score. The first quartile (red) represents patients with the
lowest NHR score, and the fourth quartile (green) represents those with the highest NHR score. Statistical analyses were performed comparing the first quartile to
the other three (p = 1.20e–16).
(legend continued on next page)
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O’Donnell et al., 2005; Schulte et al., 2008), we first scored the
patients according to their inferred MYC signaling status (Fred-
lund et al., 2008; Valentijn et al., 2012) and then sorted the pa-
tients according to their NHR scores (Figures 2B and S2A; Table
S6; Supplemental Information). There was a strong inverse rela-
tionship between the NHR score andMYCN amplification and/or
MYC signaling (both signatures p < 0.001; Figure S2A). Patients
with active MYC signaling showed low expression levels of the
predicted NHR family members and vice versa (Figure 2B), sug-
gesting an inverse correlation between NHR expression and
MYC signaling in neuroblastoma (Figure 2B; Table S6). Impor-
tantly, patients with the lowest NHR score (first quartile; Fig-
ure 2C) had significantly worse survival compared to patients
with higher NHR scores (second, third, and fourth quartiles;
Figure 2C).
Next, we investigated the impact of all NHR family members
on overall survival. Approximately half of the 42 available tran-
scripts were associated with patient outcome. These included
genes encoding the retinoic acid and steroid hormone receptors,
such as the glucocorticoid receptor (GR) and the orphan recep-
tor NURR1 (Table S7). The expression of nearly all NHR score
members, including GR, was low in MYCN-amplified tumors,
and reduced expression was associated with poor overall sur-
vival in patients (Figures 2D and S2B). Together, these data
show that several NHRs targeted by miR-1792 are downregu-
lated inMYCN-driven neuroblastoma and correlate with survival.
MYCN-Mediated Downregulation of GR Is Associated
with Neuroblastoma Tumorigenesis
To further analyze the significance of NHRs in neuroblastoma,
we focused on the GR (NR3C1) because it is (1) a direct target
of the miR-1792 cluster (Figure 1E; Vreugdenhil et al., 2009),
(2) themost significantly downregulated NHR inMYCN-amplified
patients (Figure 2A; Table S5), and (3) highly prognostic for pa-
tient outcome (Figure 2D). Additionally, GR is expressed in the
sympathetic nervous system, particularly in the adrenal gland
(Bohn et al., 1984; Parlato et al., 2009), a site where neuroblas-
toma typically arises (Maris, 2010).
We first investigated the impact of MYCN or miR-1792 on
GR protein expression in three different neuroblastoma cell lines,
with inducible expression of MYCN (MYCN3 and Tet-21/N;
Lutz et al., 1996; Slack et al., 2005) or miR-1792 (SHEP-TR-
miR-1792; Mestdagh et al., 2010). Endogenous GR levels
decreased 2-fold in the presence of either MYCN or miR-
1792 (Figure 3A). Accordingly, GR expression was reduced in
MYCN-induced cells as analyzed by immunofluorescence
(Figure 3B).
Next, we analyzed the levels of GR in the postnatal sympa-
thetic ganglia in wild-type and homozygous TH-MYCN mice, a
transgenic model of neuroblastoma where MYCN is overex-
pressed in the neural crest (Rasmuson et al., 2012; Weiss
et al., 1997). The sympathetic identity of the GR-expressing cells(D) (Upper panels) Expression levels of the NHR score transcripts comparing ne
(MYC high), and MYCN-amplified (MNA) tumors (n = 649; 278 patients in both t
survival of neuroblastoma patients in the validation cohort (n = 325) according to
score genes in the training cohort (n = 324) is shown. Patient numbers are indicawas confirmed by co-staining for tyrosine hydroxylase (TH)
(Cochard et al., 1978). We detected robust nuclear GR levels
and TH expression at postnatal day 24 (P24) in the cervical,
thoracic, and lumbar sympathetic ganglia (Figure 3C) and in
the adrenal medulla (Figure 3D) of wild-type mice.
As previously described (Hansford et al., 2004), analysis of ho-
mozygous TH-MYCN mice revealed the presence of hyper-
plastic lesions characterized by clusters of small round cells
within the sympathetic ganglia, which were not detected in
wild-type mice (Figures 3C and 3E). These hyperplasias ex-
pressed high MYCN levels but no detectable expression of the
neuronal differentiation markers TH or TrkA (Figures 3E and
4A), indicating an undifferentiated state. Conversely, mature
TH- and TrkA-positive neuronal cells in wild-type and homozy-
gous mice were MYCN-negative (Figures 3E and 4A). We did
not detect GR in MYCN-positive hyperplasias, whereas GR
expression was present in theMYCN-negative normal surround-
ing ganglionic tissue and wild-type adrenal medulla (Figures 3D
and 3E). Furthermore, an inverse relationship betweenMycn and
Nr3c1 mRNA was also observed in neural crest cells at embry-
onic day (E) 8.5 and E13.5 as well as in the adrenal medulla at
P90 in CD-1 mice (Figures 3F and 3G; Albino et al., 2011) and
in sympathetic tissue in TH-MYCN mice (Figure 3H; Heukamp
et al., 2012).
We detected tumors expressing high levels of MYCN in the
lumbar region as early as P24 (Figure S3A). Similar to the hyper-
plasias, GR expression was low or absent in P24 and adult tumor
cells (Figures S3A and S3B). Numerous scattered GR-positive
cells were present within the tumors, which were associated
with the vasculature as assessed by co-staining for the endothe-
lial marker endomucin (Figure S3C). These results show that
deregulation of GR in hyperplastic tissues is maintained during
the late stages of tumor development. We confirmed previous
studies demonstrating that miR-1792 and especially miR-18a
are highly expressed in TH-MYCN tumors compared to normal
adrenal tissue (Figure S3D; Terrile et al., 2011). Furthermore,
expression data from TH-MYCN tumors revealed an inverse rela-
tionship betweenNr3c1mRNA expression and tumormass (R2 =
0.67; Figure 3I). Nr3c1 expression was positively associated
with overall survival in these mice (Figure S3E; Balamuth et al.,
2010), aswell as in neuroblastoma patients (Figure 2D; Table S7).
Together, these results show that GR is downregulated by
MYCN through miR-1792 both in vitro and in vivo and that its
expression correlates both with an undifferentiated phenotype
and with decreased survival in neuroblastoma patients as well
as in TH-MYCN mice.
Glucocorticoid Signaling Influences the Differentiation
of Neuroblastoma
It has been suggested that the GR may regulate neuronal gene
expression in the sympathoadrenal lineage (Polman et al.,
2012). Similar to TH and GR, TrkA was readily detected in normaluroblastoma patients with low-MYC signaling (MYC low), high-MYC signaling
he MYC-low and -high groups and 93 MNA patients). (Lower panels) Overall
the prognostic expression cutoff value determined for each of the seven NHR
ted in brackets.







Figure 3. Both miR1792 and MYCN Inhibit GR Activity In Vitro and In Vivo
(A) Immunoblotting of GR and MYCN in MYCN3, Tet-21/N, and SHEP-TR-miR-1792 (TR-1792). Cells were treated with dox for 48 hr. Experiments were
performed at least five times, with the mean ± SEM reported for quantification; *p < 0.05; **p < 0.01; and ***p < 0.001, compared to either miR-1792-high or
MYCN-high states. GAPDH was used as loading control.
(B) Immunofluorescence ofGRandMYCN in Tet-21/Ncells treatedwith orwithout dox for 48 hr.One representative out of three independent experiments is shown.
(C) Immunohistochemistry for GR and TH at P24 in the sympathetic ganglia from three anatomic levels (cervical, thoracic, and lumbar). The scale bar represents
100 mm.
(D) GR expression in the adrenal medullary cells from wild-type mice, as assessed by co-expression with TH. The scale bar represents 200 mm.
(legend continued on next page)
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neuronal tissue, but not in MYCN-positive hyperplastic areas or
in tumors from TH-MYCN mice (Figures 4A and S4A), further
strengthening the notion that a deficit in GR expression is asso-
ciated with a more immature and undifferentiated phenotype.
TRKA expression has been inversely correlated toMYCN ampli-
fication and is a well-knownmarker of favorable outcome in neu-
roblastoma (Brodeur et al., 1997; Kogner et al., 1993), as also
observed in our patient cohort (Figures 4C and 4D).
To determine whether GR can directly influence neural differ-
entiation, we used a MYCN-amplified neuroblastoma cell line,
SK-N-BE(2), stably expressing either an anti-miR-18a or a
scrambled control. As previously shown, BE(2)-anti-miR-18a
cells displayed a more-differentiated phenotype compared to
control cells (Figure S4B; Love´n et al., 2010). GR expression
was significantly higher in miR-18a knockdown cells compared
to control cells (Figure 4G). In agreement with a well-described
negative feedback loop (Kalinyak et al., 1987), hydrocorti-
sone (HC) treatment induced a decrease in GR mRNA
levels in BE(2)-anti-miR18a cells (Figure 4G). In addition, neurite
outgrowth and TRKA levels increased significantly following
incubation with HC (Figures S4B and 4H), indicating that activa-
tion of GR signaling in miR18a-depleted cells induces neural
differentiation.
We further analyzed a known GR target, secretogranin II
(SCG2) (Finotto et al., 1999; Polman et al., 2012). This neuroen-
docrine protein is implicated in the packaging and sorting of hor-
mone peptides and neurotransmitters into secretory vesicles
(Ozawa and Takata, 1995) and expressed in the adrenal gland
(Figure S4C; Steiner et al., 1989). However, Scg2 is completely
absent from adrenal medullary cells in Gr-null mice (Finotto
et al., 1999), indicating that GR is required for its expression in
adrenal tissues. Importantly, SCG2 is involved in the differentia-
tion of neuroblastoma cells in vitro (Cozzi et al., 1989; Li et al.,
2008).
We detected SCG2 in cell bodies and fibers in the sympathetic
ganglia of wild-type mice (Figure 4B) as well as in TH-expressing
cells of the adrenal medulla (Figure S4C; Steiner et al., 1989).
Similar to GR, TH, and TrkA, SCG2was absent inMYCN-positive
hyperplasias and tumors in homozygous TH-MYCN mice (Fig-
ures 4B and S4D). Accordingly, SCG2 was downregulated in
neuroblastoma tumors with MYCN amplification or with high-
MYC signaling (Figure 4E), and its expression was highly prog-
nostic (Figure 4F). Moreover, the expression of SCG2 was
increased by 2-fold when miR-18a was knocked down in
MYCN-amplified neuroblastoma cells (Figure 4I), and treatment
with HC further increased mRNA levels, confirming that GR
signaling induces SCG2 expression also in BE(2)-miR-18a cells
(Figure 4I). Together, our data demonstrate that GR signaling is
increased uponmiR-18a depletion and promotes a differentiated
phenotype whereas reduced GR levels correlate with low TrkA
and SCG2 expression and an undifferentiated state.(E) H&E stain and immunohistochemistry for TH, GR, and MYCN in adjacent secti
P24 TH-MYCN mice. Three wild-type and four transgenic mice were analyzed. T
(F) Mycn mRNA expression during normal development (E8.5, E13.5, and P90) in
(G) Nr3c1 mRNA expression during normal development (E8.5, E13.5, and P90)
(H) mRNA expression levels of Nr3c1 in TH-MYCN-derived ganglia compared to
(I) Correlation between Nr3c1 mRNA expression and tumor mass in TH-MYCN mDisruption of MYC Signaling Increases GR Expression
Next, we evaluated the effect of disruption of MYC signaling
on GR expression in vivo. Hemizygous TH-MYCN mice were
treated for 6 days with vehicle or 10058-F4, a small MYC-binding
molecule that preventsMYC-MAX interaction (M€uller et al., 2014;
Yin et al., 2003; Zirath et al., 2013). Treatment with 10058-F4
increased the number of GR-positive cells by 50% compared
to the vehicle-treated tumors (Figures S5A and S5C). Most
GR-positive cells detected in vehicle-treated hemizygous tu-
mors were endothelial cells (Figure S5B). Despite some overlap
between GR and MYCN, GR-positive cells were generally nega-
tive for MYCN (Figure S5A; high magnification). These results
indicate that disruption of MYC signaling increases the number
of GR-positive tumor cells in vivo. Furthermore, GR-expressing
cells not associated with the vasculature were positive for TH,
indicating a more-differentiated phenotype (Figure S5D).
Pharmacological Inhibition of MYCN followed by
Activation of GR Signaling Promotes Differentiation and
Reduces Tumor Burden
Next, we addressed the functional role of GR signaling in neuro-
blastoma biology. SK-N-BE(2) cells were treated for 6 days with
dexamethasone (DEX), a synthetic ligand of GR, and with 10058-
F4, alone and in combinationwhere DEXwas added after 72 hr of
pre-treatment with 10058-F4 (10058-F4+DEX; Figures S6A and
5A–5G). We found that expression of miR-17, miR-18a, and
miR-19a was decreased by all treatments, with the most-robust
effect in the 10058-F4+DEX combination (Figure S6B). Treat-
ment with 10058-F4 reduced MYCN levels (Figures 5A and 5D;
Zirath et al., 2013), whereas GR expression was upregulated,
which is consistent with an inverse relationship between
MYCN and GR (Figures 5A and 5E). Whereas no changes in
MYCN were observed with DEX treatment alone, the 10058-
F4-induced reduction of MYCN was further decreased in the
combination treatment (10058-F4+DEX; Figures 5A and 5D).
As expected, DEX, alone or with 10058-F4, promoted a
decrease in GR levels (Figures 5A and 5E; Kalinyak et al.,
1987). The effects on GR and MYCN expression were confirmed
using two other MYC inhibitors, 10074-G5 and JQ1, separately
and in combination with DEX as well as by incubating the
MYCN-amplified KCN69n cell line with 10058-F4 and DEX alone
and in co-treatment (Figures S6C and S6D).
To evaluate the impact of activation of GR signaling inMYCN-
amplified neuroblastoma, we assessed the expression of poly
(ADP-ribose) polymerase (PARP), proliferating cell nuclear anti-
gen (PCNA), and TrkA, markers for apoptosis, cell proliferation,
and differentiation, respectively. Whereas full-length PARP
was detected in all conditions, cleaved PARP was only present
following treatment with 10058-F4 and increased when 10058-
F4 was combined with DEX (Figure 5B). In contrast, PCNA levels
were reduced following 10058-F4 incubation and were furtherons of the superior cervical ganglia in age-matched wild-type and homozygous
he scale bar represents 100 mm.
wild-type mice (Albino et al., 2011).
in wild-type mice (Albino et al., 2011).
wild-type adrenal tissue (normal; Heukamp et al., 2012).
ice (p < 0.001; R2 = 0.67; Balamuth et al., 2010).
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Figure 4. GR Expression and Signaling Correlate to Increased Expression of Differentiation Markers Both In Vitro and In Vivo
(A) Immunohistochemistry for TH, GR, and TrkA in adjacent sections of the superior cervical ganglia in wild-type and homozygous P24 TH-MYCNmice. The scale
bar represents 100 mm.
(B) Immunohistochemistry for TH, SCG2, and MYCN in adjacent sections of the superior cervical ganglia in age-matched wild-type and homozygous P24 mice.
The scale bar represents 100 mm.
(C) Expression levels of TRKA comparing neuroblastoma patients with low-MYC signaling (MYC low), high-MYC signaling (MYC high), and MYCN-amplified
(MNA) tumors (n = 649, 278 patients in both the MYC-low and -high groups and 93 MNA patients).
(D) A Kaplan-Meier plot based on TRKA mRNA expression levels correlated to overall survival. Neuroblastoma patients (n = 649) categorized into four equally
sized quartile groups based on TRKA expression are shown. The quartile with the lowest expression is shown in purple (p < 0.001).
(E) Expression levels of SCG2 comparing neuroblastoma patients with low-MYC signaling (MYC low), high-MYC signaling (MYC high), and MYCN-amplified
(MNA) tumors (n = 649, 278 patients in both the MYC-low and -high groups and 93 MNA patients).
(F) A Kaplan-Meier plot based on the SCG2 mRNA expression levels correlated to overall survival. Neuroblastoma patients (n = 649) were categorized into four
equally sized quartile groups based on SCG2 expression levels. The quartile with the lowest expression is shown in purple (p < 0.001).
(G) qPCR analysis of NR3C1 (GR) expression in SK-N-BE(2) cells transduced with either a scrambled-miRNA (scramble) or an anti-miR-18a (anti-miR-18a)
lentivirus and treated with and without the natural ligand hydrocortisone (HC). n = 5 (*p < 0.05).
(H) qPCR analysis of TRKA expression in SK-N-BE(2) cells transduced with either a scrambled-miRNA (scramble) or an anti-miR-18a (anti-miR-18a) lentivirus and
treated with and without hydrocortisone (HC). n = 5 (***p < 0.001).
(I) qPCR analysis of SCG2 expression in SK-N-BE(2) cells transduced with either a scrambled-miRNA (scramble) or an anti-miR-18a (anti-miR-18a) lentivirus
treated with and without hydrocortisone (HC). n = 5 (**p < 0.01; ***p < 0.001).decreased upon DEX addition (Figure 5C). We found that DEX
moderately increased TrkA whereas 10058-F4 led to a more-
robust TrkA expression, both alone and in combination with
DEX (Figures 5F and 5G).986 Cell Reports 16, 979–993, July 26, 2016Next, we analyzed the role of GR in differentiation in cells
derived from the TH-MYCNmouse model. Tumor cells were iso-
lated and grown as spheres that differentiated into TH-positive
sympathetic neurons under differentiation conditions (Figure 5H).
Figure 5. Inhibition of MYCN followed by Activation of GR Signaling Promotes Neural Differentiation
(A–C) Immunoblotting of GR andMYCN (A), PARP (B), and PCNA (C) in the SK-N-BE(2) cell line. Cells were incubated for 6 days with DEX and/or 10058-F4, alone
and in combination, where DEX and 10058-F4 were added after 72 hr of pre-treatment with 10058-F4 (10058-F4+DEX). Control cells were treated with DMSO,
DEX, or both in combination after DMSO pre-incubation (DMSO+DEX). See Figure S6A for experimental scheme. Representative blots from five experiments are
shown. a-tubulin was used as a loading control.
(D and E) Quantification of MYCN (D) andGR (E) by densitometry. n = 5 with themean ±SEM shown for quantification; *p < 0.05 compared to DMSO-treated cells.
(F) Quantification of TrkA immunofluorescence in treated SK-N-BE(2) cells. n = 5 with the mean ± SEM shown for quantification; **p < 0.01 compared to DMSO-
treated cells.
(G) Immunofluorescence of TrkA in treated SK-N-BE(2) cells. One representative out of five independent experiments is shown. The scale bar represents 25 mm.
(H) Proliferation and differentiation of TH-MYCN spheres. Bright field microscopy pictures in two different magnifications of tumor spheres in proliferation or
differentiation conditions as indicated are shown. Immunofluorescence of TH (red) and GR (green) is shown. DAPI (blue) stains the DNA. The scale bars represent
25 mm.
(legend continued on next page)
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Notably, when proliferating spheres were induced to differen-
tiate, GR expression was upregulated with a concomitant reduc-
tion in MYCN levels (Figure 5I). In addition, we observed that the
majority of neurons co-expressed GR and TH (Figure 5H). We
employed our scheme with 10058-F4 and DEX (Figure S6A) on
the TH-MYCN-derived tumor spheres. As expected, 10058-F4
induced a decrease in MYCN levels with a concomitant upregu-
lation in GR (Figures 5J–5L). DEX also promoted a reduction
in MYCN levels, and the combination treatment with 10058-F4
potentiated this decrease (Figures 5J and 5K). Importantly,
both DEX and 10058-F4 stimulated an increase in TH expres-
sion, which was further enhanced when both compounds
were used together (Figures 5J and 5M). As in SK-N-BE(2)
cells, all treatments resulted in a reduced expression of miR-
17, miR-18a, and miR19a, particularly the combination treat-
ment (Figure S6E).
To further clarify the role of GR in neuroblastoma differentia-
tion, we generated SK-N-BE(2) neuroblastoma cells stably ex-
pressing GR using a cumate-inducible lenti-vector. As control,
cells were transduced in parallel with an empty vector. Whereas
GR was low or undetectable in the control BE(2)-EV cells, we
observed GR expression in the BE(2)-GR cells even in the
absence of cumate, indicating certain leaky gene expression
(Figures 6A, 6B, S6F, and S6G). However, cumate promoted a
robust dose-dependent induction of GR followed by a modest
reduction in MYCN levels (Figures S6F–S6H). Importantly, GR
overexpression stimulated TH levels, which were further
increased by DEX treatment (Figures 6B and 6C).
Together, our data reveal that activation of GR signaling
following MYCN inhibition promotes neuronal differentiation,
while reducing cell proliferation and stimulating apoptosis. Simi-
larly, GR overexpression in MYCN-amplified neuroblastoma
cells stimulates neural differentiation, which in turn is potentiated
by DEX treatment, further supporting a role for GR signaling in
promoting neural differentiation (Figures 6B and 6C).
To evaluate the therapeutic potential of activation of GR
signaling inMYCN-amplified neuroblastoma, we performed xen-
otransplantation experiments in which nude mice were injected
subcutaneously with SK-N-BE(2) cells followed by treatment
with 10058-F4 and DEX alone and in combination (Figure S7A).
By day 5, we observed a significant decrease in both tumor vol-
ume and in tumor volume index in all treated animals compared
to vehicle-treated mice (Figures 6D and S7B). Importantly, at the
endpoint, this decline was only maintained in the DEX10 and
10058-F4+DEX10 groups, with a stronger effect in the latter (Fig-
ure 6D). These results were corroborated by analysis of tumor
weight (Figure 6E). In agreement with the in vitro experiments,
a robust decrease in MYCN levels was only detected in the com-
bination treatment, whereas no significant changes were de-
tected in tumors from other treatment groups (Figures 6F, 6G,(I) Immunoblotting of GR, MYCN, and PCNA during proliferation and differentiation
a-tubulin was used as loading control.
(J) Immunoblotting of GR andMYCN, PCNA, and TH in spheres from the TH-MYCN
in a combination, where DEX and 10058-F4were added together after 72 hr of pre-
DEX alone and in combination (DMSO+DEX). Representative blots from five exp
(K–M) Quantification of MYCN (K), GR (L), and TH (M) by densitometry. n = 5 with th
for MYCN and TH and compared to DMSO+DEX for GR.
988 Cell Reports 16, 979–993, July 26, 2016and S7C). In conclusion, our results reveal MYCN inhibition fol-
lowed by activation of glucocorticoid signaling as a potential
new combination therapy for treating high-risk,MYCN-amplified
neuroblastoma patients.
DISCUSSION
Both MYCN amplification (Brodeur, 2003) and MYC signaling
(Fredlund et al., 2008; Valentijn et al., 2012) correlate with
aggressive tumor growth and poor prognosis in neuroblastoma.
Our study identifies several members of the NHR superfamily as
targets of the miR-1792 cluster and shows that NHR expres-
sion correlates to survival in neuroblastoma patients. Seven pu-
tative miR-1792 NHR targets (NHR score) were significantly
inversely correlated withMYCN amplification and MYC pathway
activity. Importantly, a high NHR score and expression of individ-
ual NHRs were significantly associated with increased survival,
indicating an important role for NHRs in neuroblastoma biology.
We also found that the co-activator NCOA1, which enhances
the activity of several NHRs (Onate et al., 1998), is regulated by
the miR-1792 cluster, supporting widespread control of NHR
activity by this miRNA family. Given the neural origin of neuro-
blastoma, it is important to note that many of these NHRs play
essential roles in neural development (e.g., NURR1 and liver X re-
ceptors; Sacchetti et al., 2009; Zetterstro¨m et al., 1997) and in
the differentiation of neurons (e.g., mineralocorticoid receptor;
Munier et al., 2010).
The GR has been implicated in several neural development
processes, including cell proliferation, brain growth, and remod-
eling of axons and dendrites (Meyer, 1983, 1985). In the sympa-
thetic nervous system, GR is expressed in the ganglia (Bohn
et al., 1984) and in medullary adrenal chromaffin cells, where it
promotes expression of catecholaminergic characteristics
(Smith and Fauquet, 1984). Given that neurohormone expression
is linked with differentiation, these studies underline the impor-
tance of glucocorticoid signaling in neuronal maturation. We
only detected nuclear GR in the sympathetic ganglia during the
postnatal stages, further strengthening the concept that GR
expression is associated with (or a property of) terminally differ-
entiated sympathetic neuronal cells.
MYCN plays a crucial role in the migration of neural crest
cells during development but is turned off in mature neural cells
(Zimmerman et al., 1986). Interestingly, Gr expression is low
during mouse embryonic development of sympathetic ganglia,
whereas Mycn expression is high; however, this relationship
becomes inverted after birth. We suggest that persistent high
MYCN levels may contribute to neuroblastoma development
by repressing several NHRs through miR-1792, thereby
rendering the cells unresponsive to hormones and other ligands
required for final neuronal differentiation (Figure 7). Our dataof TH-MYCN spheres. Representative blots from five experiments are shown.
tumors. Spheres were treated for 6 days with DEX or 10058-F4 separately and
treatment with 10058-F4 (Figure S6A). Control cells were treatedwith DMSO or
eriments are shown. a-tubulin was used as loading control.
e mean ± SEM shown for quantification; *p < 0.05 compared to DMSO-treated
(legend on next page)
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Figure 7. Links among miR-1792, NHRs, and Neuroblastoma Patient Outcome
Model illustrating repression of NHR family members by theMYCN-drivenmiR1792 cluster in neuroblastoma. Many NHRs are linked to neuronal differentiation/
maturation, and low expression levels are associated with decreased survival inMYCN-amplified patients, suggesting that hormonal unresponsiveness may be a
contributing factor in neuroblastoma aggressiveness. GR is a direct miR-1792 target, which upon activation by DEX stimulates expression of the neuronal
differentiation markers TH, TrkA, and SCG2. CBP, cyclic AMP response element-binding protein, a co-activator; GR, glucocorticoid receptor; H, hormone; L,
ligand; NCO1A, nuclear co-activator 1; NHR, nuclear hormone receptor; p300: a co-activator; SCG2, secretogranin 2; TH, tyrosine hydroxylase; TrkA, tropo-
myosin receptor kinase A.show that GR expression and responsiveness to glucocorticoids
is intrinsic to sympathetic neurons and promotes their differen-
tiation. Upon MYCN amplification, neuroblasts/neurons that
would otherwise express GR fail to initiate or maintain its expres-
sion and retain their proliferative status. We further showed that
hyperplasias in the ganglia of TH-MYCN mice with increased
MYCN levels were devoid of GR and of differentiation markers,
which were otherwise expressed in the surrounding normal
tissue. Moreover, GR signaling led to upregulation of TrkA,
SCG2, and TH in vitro, indicating that GR contributes to the dif-
ferentiation of neural cells.
The current treatment for high-risk patients includes intensive
chemotherapy followed by surgery, myeloablative chemo-
therapy with autologous stem cell rescue, retinoid treatment,
and immunotherapy (Øra and Eggert, 2011). Although most pa-
tients initially respond to therapy, many succumb to relapse
and therapy resistance (Mueller and Matthay, 2009). The differ-
entiation agent 13-cis retinoic acid is used as maintenance ther-
apy for high-risk patients in remission (Matthay et al., 2009; YuFigure 6. Increased Neural Differentiation and Reduced Tumor Burden
(A) Immunofluorescence of GR in BE(2)-EV and BE(2)-GR cells. Cells were trea
combination of cumate and DEX for 4 days. DEX treatment resulted in transloca
periments are shown. The scale bar represents 25 mm.
(B) Immunoblotting of GR, MYCN, and TH in BE(2)-GR cells and in control BE(2)-E
as indicated. One representative blot from six experiments is shown. a-tubulin w
(C) Quantification of TH by densitometry in BE(2)-EV and BE(2)-GR cells. n = 6 w
(D) Tumor volume index (TVI) in a xenograft model of SK-N-BE(2) neuroblastoma c
DEX (1 and 10 mg/kg), 10058-F4 (25 mg/kg), or the combination of 10058-F4
F4+DEX10). See Figure S7A for experimental scheme. n = 6 for the vehicle (DMS
group. The mean ± SEM is shown for quantification; *p < 0.05; **p < 0.01; ***p <
(E) Tumor weights at the end of treatment. n = 6 for the vehicle (DMSO), DEX10,
mean ± SEM is shown for quantification; *p < 0.05.
(F) Quantification of the MYCN levels in all the treated tumors normalized by tota
(G) Immunohistochemistry for MYCN in tumor sections from treated mice. Thr
Representative sections are presented.
990 Cell Reports 16, 979–993, July 26, 2016et al., 2010). Our in vivo findings reveal that a combined thera-
peutic approach could be beneficial for neuroblastoma patients.
We propose that drugs that disrupt the expression or function of
MYCN/MYC or agents that inhibit the miR-1792 cluster would
render these tumors more responsive to differentiation, thereby
promoting hormone treatment (e.g., corticoids). Indeed, aliser-
tib, a highly selective inhibitor of the MYCN-stabilizing aurora A
kinase, and miravirsen, a miRNA inhibitor, are already in clinical
trials (Brockmann et al., 2013; Janssen et al., 2013). Importantly,
DEX is commonly used together with chemotherapy to treat
certain types of cancer (Inaba and Pui, 2010; Pui and Evans,
2006). Our findings offer a potential alternative combination
therapy that is particularly beneficial for high-risk neuroblastoma
patients and that could promptly be translated into a clinical
setting.EXPERIMENTAL PROCEDURES
Detailed materials andmethods are provided in the Supplemental Information.upon Activation of GR Signaling
ted for 6 days where cells were pre-incubated with cumate for 2 days and a
tion of cytoplasmic GR into the nucleus. Representative pictures from six ex-
V cells with or without induction with cumate in the presence or absence of DEX
as used as loading control.
ith the mean ± SEM is shown for quantification.
ells, in which the mice were treated with vehicle (DMSO), two different doses of
pre-treatment followed by 10058-F4 together with 10 mg/kg DEX (10058-
O), DEX10, 10058-F4, and 10058-F4+DEX10 groups, and n = 5 for the DEX1
0.001; and ****p < 0.0001 compared to vehicle (DMSO).
10058-F4, and 10058-F4+DEX10 groups; and n = 5 for the DEX1 group. The
l protein amount. The mean ± SEM is shown for quantification; *p < 0.05.
ee tumors per treatment were analyzed. The scale bar represents 200 mm.
In Silico Prediction and Expression Analysis
TargetScan, PicTar2,miRanda, andmirTarget2 were used for target prediction
of miR-1792 family members. The NHR score was generated by ranking the
seven genes that were predicted targets as well as downregulated in MYCN-
amplified neuroblastoma patients (NR3C1, NR4A2, RORA, NR4A3, ESR1,
NR3C2, and NCOA1; Table S6) from lowest to highest across all patients.
We employed two gene expression signatures (Fredlund et al., 2008; Valentijn
et al., 2012) to infer MYC signaling. All patients were registered in the respec-
tive clinical trials with written informed consent from the patient and/or the par-
ents or legal guradian.
Protein Expression
Western blot and immunohistochemistry (IHC) analyses were performed as
described (Zirath et al., 2013). For IHC on mouse tissues, 14-mm transverse
sections from cryosections were pre-incubated for 1 hr in blocking solution
(PBS, 0.25% Triton X-100, and 5% normal goat serum) followed by incubation
at 4C overnight with the primary antibodies diluted in blocking solution. After
washing, the slides were incubated for 1–2 hr at room temperature with the
appropriate fluorophore-conjugated antibodies. Antibodies are listed in the
Supplemental Information.
Animal Experiments
For xenografts studies, 10 3 106 SK-N-BE(2) cells were subcutaneously in-
jected in the flanks of nudemice. Tumor take was defined as the point at which
tumors reached 0.15 cm3. Mice were treated for 7 days with vehicle (DMSO),
10058-F4 (25 mg/kg), two different doses of DEX (1 mg/kg and 10 mg/kg), or
pretreated with 10058-F4 for 72 hr followed by a combination of 10054-F4 and
DEX10 for 4 days (10054-F4+DEX10). As controls, DEX-treated mice were
administered DMSO for 72 hr followed by DMSO+DEX10 treatment for 4 days.
NMRI-Foxn1nu and TH-MYCN were housed, bred, treated, and analyzed in
accordance with the permits approved by the Swedish ethical committee
Stockholms Norra Djurfo¨rso¨ksetiska Na¨mnd (ethical approval numbers
N231/14 for NMRI-Foxn1nu and N26/11, N42/14, and N71/15 for TH-MYCN).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.06.052.
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